Center for Developmental Genetics, Program in Molecular & Cellular Pharmacology and, Department of Pharmacology, Stony Brook University, Stony Brook, NY 11794, USA.
Future Oncol. 2009 Nov;5(9):1477-86. doi: 10.2217/fon.09.110.
Phospholipase D (PLD)1 and PLD2, the classic mammalian members of the PLD superfamily, have been linked over the past three decades to immune cell function and to cell biological processes required by cancer cells for metastasis. However, owing to the lack of effective small-molecule inhibitors, it has not been possible to validate these roles for the PLDs and to explore the possible utility of acute and chronic PLD inhibition in vivo. The first such inhibitors have recently been described and demonstrated to block neutrophil chemotaxis and invasion by breast cancer cells in culture, increasing the prospects for a new class of therapeutics for autoimmune disorders and several types of metastatic cancer.
磷脂酶 D (PLD)1 和 PLD2 是经典的哺乳动物 PLD 超家族成员，在过去的三十年中，它们与免疫细胞功能以及癌细胞转移所需的细胞生物学过程有关。然而，由于缺乏有效的小分子抑制剂，一直无法验证这些 PLD 的作用，也无法探索急性和慢性 PLD 抑制在体内的可能用途。最近，首次描述并证明了第一批此类抑制剂可以阻断中性粒细胞趋化性和乳腺癌细胞在培养中的侵袭，这增加了为自身免疫性疾病和几种转移性癌症开发一类新治疗药物的前景。
